Compass Pathways Stock News

This week, we're talking about my Big Three investing themes for the rest of the year (and beyond). You've probably heard me talk about each at one point or another.

These two trends on the frontier of medicine could present lucrative opportunities for investment.

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts a

Wall Street is growing increasingly bullish about the drugmaker's prospects.

Here's why OrthoPediatrics, Compass Pathways, and Nano-X Imaging look like great stocks.

COMPASS Pathways is developing a psychedelic drug to treat many mental illnesses. The drug appears to be safe and effective for a wide range of mental health problems.

The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Steven Schultz - Senior Vice President, Investor Relations George Goldsmith - Co-Fou

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan

The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric

COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Chairman & CEO Guy Goodwin - Chief Medical

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, annou

And other market news.

NEW YORK , March 2, 2022 /PRNewswire/ -- Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can''t be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces stress-induced neuroplasticity, which plays a critical role in almost all mental disorders. The problem is conventional drugs have done little to correct damage in this response, resulting in mental health disorders that now affect nearly one in every eight people on the planet. Amazingly, research with psychedelic therapeutics has shown great promise, inspiring hope in treating a broad range of mental health disorders. With the urgent need for new, more effective treatments to treat a wide spectrum of disorders, Cybin Inc. (NEO: CYBN)(NYSE: CYBN )( Profile ) is pioneering groundbreaking research and striking important partnerships to unleash the power of these psychedelic-based compounds. Cybin has a differentiated method of progressing psychedelics into therapeutics than others in the sector, such as COMPASS Pathways Plc (NASDAQ: CMPS ), Mind Medicine Inc. (NASDAQ: MNMD ) (NEO: MMED), ATAI Life Sciences N.V . (NASDAQ: ATAI ) and GH Research PLC (NASDAQ: GHRS ), which are also intent on offering effective solutions.